VSL#3 is a probiotic scientifically formulated to keep your gut healthy and support your wellbeing. VSL#3 Probiotic supplement offers a high concentration of diverse bacteria strains that have been specially selected and then freeze dried, allowing them to survive the harsh conditions of the stomach and get to where they are needed most. Your Gut.
VSL#3 should be kept refrigerated but can be kept at room temperature for up to 7 days making it perfect to take with you wherever you go. VSL#3 is super convenient, easy to take and effective, making it the ideal choice of supplement for your Gut health.
VSL#3 DS delivers 900 billion bacteria per packet (up to 22.5 times more potent than the average probiotic) and consists of 8 strains of live, freeze-dried lactic acid bacteria. It is the only probiotic recognized as an effective tool in the dietary management of ileal pouch by the American College of Gastroenterology1 and by the Cochrane Review2.
The VSL#3 DS PAP varies with each patient depending on individual evaluation. The eligibility criteria for this program is that the patient must have an applicable diagnosis or physician referral, be a legal U.S. resident, and must meet a financial need criteria.Decisions for coverage are usually announced within two business days after applying. The product is shipped directly to the patient, and one can reapply for assistance every November to ensure continued supply of the probiotic.
VSL#3 (VSL#3) is a high-concentration probiotic preparation of eight live freeze-dried bacterial species that are normal components of the human gastrointestinal microflora, including four strains of lactobacilli (Lactobacillus casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. breve and B. infantis) and Streptococcus salivarius subsp. thermophilus.
Categorized as a medical food source, VSL #3 is a probiotic that helps keep the digestive tract healthy and working well. It does this by introducing all the different types of bacteria found there under normal conditions, but which may be missing because of illness.
VSL #3 contains a probiotic mixture of eight different bacteria including four strains of lactobacilli, three strains of bifido bacteria, and streptococcus salivarius subsp. thermophilus. The bacteria are freeze-dried live and made into a powder. VSL #3 is available in tablet and powder form.
The national average cost for a box of 20 packets of soluble powder of VSL #3 DS 900 billion cfu is around $160.00. Your final price may be slightly higher or lower depending on where you live and where you purchase the product.
Yes, it is possible to have diarrhea when you first start to take probiotics. Probiotics alter the microbiome, so when they are first introduced, some people may experience temporary symptoms such as gas, bloating, diarrhea, and abdominal cramps. These symptoms will dissipate after a few days.
There have been a few cases where diarrhea resulting from probiotic use may be a sign of more severe complications. Issues like sepsis and fungus in the blood may occur in people who are already severely ill or have compromised immune systems. For those with healthy immune systems, symptoms will be temporary. If diarrhea persists past a few days, it may be a good idea to stop the probiotic supplement.
Our gut microbiome has 109 microorganisms, so it would be quite difficult to ingest enough probiotic supplements to overpower these. However, it is possible that taking too many can trigger uncomfortable symptoms such as gas, bloating, abdominal cramping, and diarrhea.
Research is growing with respect to using a specific combination of probiotics in preterm, low-birth-weight infants born before 37 weeks gestation for the prevention of necrotizing enterocolitis. Even with the research, probiotics are not appropriate for all preterm, low-birth-weight infants.
Martín-Muñoz MF, Fortuni M, Caminoa M, Belver T, Quirce S, Caballero T. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. Pediatr Allergy Immunol. 2012;23(8):778-784. doi:10.1111/j.1399-3038.2012.01338.x
The gut microbiota modulates the autoimmune pathogenesis of type 1 diabetes (T1D) via mechanisms that remain largely unknown. The inflammasome components are innate immune sensors that are highly influenced by the gut environment and play pivotal roles in maintaining intestinal immune homeostasis. In this study we show that modifications of the gut microbiota induced by oral treatment with Lactobacillaceae-enriched probiotic VSL#3, alone or in combination with retinoic acid (RA), protect NOD mice from T1D by affecting inflammasome at the intestinal level. In particular, we show that VSL#3 treatment inhibits IL-1β expression while enhancing release of protolerogenic components of the inflammasome, such as indoleamine 2,3-dioxygenase (IDO) and IL-33. Those modifications of the intestinal microenvironment in VSL#3-treated NOD mice modulate gut immunity by promoting differentiation of tolerogenic CD103+ DCs and reducing differentiation/expansion of Th1 and Th17 cells in the intestinal mucosa and at the sites of autoimmunity, that is, within the pancreatic lymph nodes (PLN) of VSL#3-treated NOD mice. Our data provide a link between dietary factors, microbiota composition, intestinal inflammation, and immune homeostasis in autoimmune diabetes and could pave the way for new therapeutic approaches aimed at changing the intestinal microenvironment with probiotics to counterregulate autoimmunity and prevent T1D.
Here, we demonstrate that administration of the Lactobacillaceae-enriched VSL#3 probiotic, alone or in combination with RA, prevents T1D in NOD mice by enriching the local microbiota with Lactobacillaceae strains and by inducing substantial modifications in the microbiota composition with increase in Clostridia and Rikenellaceae species and reduction in the Bacteroidetes strain S24-7. In addition, VSL#3 administration and the resulting microbiota modifications generate a protolerogenic intestinal microenvironment with high expression of IDO and low expression of inflammatory IL-1β. The VSL#3-induced protolerogenic microenvironment promoted CD103+ DC differentiation and reduced the Teff/Treg cell ratios within the gut mucosa, mesenteric lymph nodes (MLN), and PLN, thereby modulating T1D pathogenesis.
A previous report has shown that administration of the probiotic VSL#3 confers protection against T1D in NOD mice . We repeated the experiment to assess the mechanism underlying VSL#3-mediated protection and to verify whether it could be enhanced by simultaneous administration of all-trans-RA, a vitamin A metabolite that critically modulates gut immunity . NOD mice received the VSL#3 probiotic via weekly gavage administration starting at 4 weeks of age until 20 weeks of age. An additional group of NOD mice received VSL#3 in combination with RA while the control group received PBS only by gavage. As shown in Figure 1(a), we confirmed that administration of VSL#3 alone significantly protected NOD mice from T1D and the combination therapy with VSL#3 and RA did not increase protection from autoimmune T1D. The protective effect of VSL#3 treatment was confirmed at the histological level and NOD mice receiving VSL#3 with or without RA showed reduced degree of insulitis compared to their nontreated littermates (Figures 1(b) and 1(c)). Next, we aimed to identify the mechanisms underlying VSL#3- and VSL#3 + RA-mediated T1D protection. Although it was hypothesized that VSL#3, which is a probiotic enriched in Lactobacillaceae strains, prevented T1D by favoring colonization of the intestine of NOD mice with beneficial bacteria, comparative analysis of the microbiota profiles in VSL#3-treated and untreated NOD mice has never been performed. We analyzed at the phylum, class, order, family, and genus level the composition of the intestinal fecal community by ultradeep pyrosequencing of barcoded 16S rRNA gene amplicons in NOD mice treated with VSL#3 or VSL#3 + RA or in control NOD mice that were either untreated or treated with RA alone. As shown in Figure 2, administration of VSL#3 to NOD mice with/without RA induced a substantial change in the microbiota profile by increasing the relative abundance of some bacterial strains such as Clostridia species, which have strong protolerogenic properties and the capacity to induce immune tolerance and to reduce inflammation within intestinal tissues [27, 28]. On the other hand, bacterial strains belonging to the Bacteroidaceae family (strain S24-7) were strongly reduced in the VSL#3-protected mice, thus suggesting that those strains may have proinflammatory effects and a pathogenic role in T1D. Other strains of Bacteroidetes, such as the Rikenellaceae strains, were increased in the VSL#3-protected mice, indicating that the beneficial and pathogenic microbiota profiles were not regulated at the family level but were possibly linked to the relative abundance of the specific bacterial strains.
The effect on the inflammatory environment of the VSL#3 probiotic can be integrally related to modulation of intestinal DCs. Intestinal DCs are instrumental to sense environmental modifications in the gut mucosa and acquire a specific inflammatory or tolerogenic functional phenotype to build adaptive immune response against pathogens or induce immune tolerance against innocuous microbiota and food components. For example, intestinal DCs that express the surface marker CD103 and have tolerogenic function through secretion of soluble factors such as IDO and IL-10 [40, 41]. On the other hand, CD11c+CX3CR1+ cells are involved in transfer of the soluble luminal antigens to CD11c+CD103+ DCs via the gap junctions to induce immune tolerance . Importantly, we found that the microbiota modifications induced by VSL#3 in the NOD mice reduced the increased inflammatory environment and IL-1β by